Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood thinner aims to cut bleeding risk in AF patients

NCT ID NCT04755283

Disease control Sponsor: Anthos Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study compares abelacimab, a new biologic blood thinner, to the standard drug rivaroxaban in 1,287 people with atrial fibrillation who are at moderate-to-high risk of stroke. The goal is to see if abelacimab causes fewer major or clinically relevant bleeding events while still preventing strokes. Participants receive either abelacimab or rivaroxaban, and researchers track bleeding rates over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
abelacimab (a biologic blood thinner)
What this could lead to
If successful, abelacimab could offer a safer blood-thinning option for people with atrial fibrillation, reducing bleeding risks while still preventing strokes.
What could go wrong
This is a mid-stage trial with 1,287 participants, so results are not final. The drug may still cause bleeding or fail to prevent strokes as well as rivaroxaban.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

1,287 people

The number who actually took part.

Started

Feb 2021

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients ≥ 55 years old * Patients with a history of atrial fibrillation (AF) or atrial flutter with planned indefinite anticoagulation * Patients with a CHA2DS2-VASc of ≥4 OR a CHA2DS2-VASc of ≥3 with at least 1 of the following: 1. Planned concomitant use of antiplatelet medication use (i.e., aspirin and/or P2Y12 inhibitor) for the duration of the trial 2. Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation Exclusion Criteria: * History of hypersensitivity to any of the study drugs (including rivaroxaban) or its excipients, to drugs of similar chemical classes, or any contraindication listed in the label for rivaroxaban * Patients with an intracranial or intraocular bleed within the 3 months prior to screening * Clinically significant mitral stenosis (valve area \<1.5 cm2) * Mechanical heart valve or other indication for anticoagulation therapy other than atrial fibrillation (e.g., venous thromboembolism) * Known presence of an atrial myxoma or left ventricular thrombus * History of left atrial appendage closure or removal * Active endocarditis Other protocol defined Inclusion/Exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF) Stroke

Contacts and locations

Locations

  • Anthos Investigative Site

    Huntsville, Alabama, 35801, United States

  • Anthos Investigative Site

    Mobile, Alabama, 36608, United States

  • Anthos Investigative Site

    Stamford, Connecticut, 06905, United States

  • Anthos Investigative Site

    Clearwater, Florida, 33756, United States

  • Anthos Investigative Site

    Daytona Beach, Florida, 32114-2321, United States

  • Anthos Investigative Site

    Largo, Florida, 33777, United States

  • Anthos Investigative Site

    Safety Harbor, Florida, 34695, United States

  • Anthos Investigative Site

    Saint Augustine, Florida, 32086, United States

  • Anthos Investigative Site

    Johns Creek, Georgia, 30024, United States

  • Anthos Investigative Site

    Owensboro, Kentucky, 42303, United States

  • Anthos Investigative Site

    Baltimore, Maryland, 21229-5222, United States

  • Anthos Investigative Site

    Salisbury, Maryland, 21804, United States

  • Anthos Investigative Site

    Framingham, Massachusetts, 01701, United States

  • Anthos Investigative Site

    Haverhill, Massachusetts, 01830, United States

  • Anthos Investigative Site

    Lansing, Michigan, 48912, United States

  • Anthos Investigative Site

    Sewell, New Jersey, 08080, United States

  • Anthos Investigative Site

    Poughkeepsie, New York, 12601, United States

  • Anthos Investigative Site

    Southampton, New York, 11968, United States

  • Anthos Investigative Site

    Lenoir, North Carolina, 28645, United States

  • Anthos Investigative Site

    Fargo, North Dakota, 58104, United States

  • Anthos Investigative Site

    Oklahoma City, Oklahoma, 73135, United States

  • Anthos Investigative Site

    Camp Hill, Pennsylvania, 17011, United States

  • Anthos Investigative Site

    Kingsport, Tennessee, 37660, United States

  • Anthos Investigative Site

    Kingwood, Texas, 77339, United States

  • Anthos Investigative Site

    Odessa, Texas, 79761-5133, United States

  • Anthos Investigative Site

    Tomball, Texas, 77375, United States

  • Anthos Investigative Site

    Falls Church, Virginia, 22042, United States

  • Anthos Investigative Site

    Manassas, Virginia, 20109, United States

  • Anthos Investigative Site

    Cambridge, Ontario, N1R 7R1, Canada

  • Anthos Investigative Site

    Greater Sudbury, Ontario, P3B 4H5, Canada

  • Anthos Investigative Site

    Oshawa, Ontario, L1J2K1, Canada

  • Anthos Investigative Site

    Greenfield Park, Quebec, J4V 2G8, Canada

  • Anthos Investigative Site

    Montreal, Quebec, H1T 3Y7, Canada

  • Anthos Investigative Site

    Brandýs nad Labem, Central Bohemia, 250 01, Czechia

  • Anthos Investigative Site

    Poděbrady, Central Bohemia, 29001, Czechia

  • Anthos Investigative Site

    Příbram, Central Bohemia, 261 01, Czechia

  • Anthos Investigative Site

    Slaný, Central Bohemia, 274 01, Czechia

  • Anthos Investigative Site

    Mariánské Lázně, KA, 353 01, Czechia

  • Anthos Investigative Site

    Trutnov, KR, 541 01, Czechia

  • Anthos Investigative Site

    Liberec, LB, 460 01, Czechia

  • Anthos Investigative Site

    Česká Lípa, LI, 470 01, Czechia

  • Anthos Investigative Site

    Liberec, LI, 460 01, Czechia

  • Anthos Investigative Site

    Pardubice, PA, 530 02, Czechia

  • Anthos Investigative Site

    Prague, PR, 10100, Czechia

  • Anthos Investigative Site

    Prague, PR, 110 00, Czechia

  • Anthos Investigative Site

    Prague, PR, 158 00, Czechia

  • Anthos Investigative Site

    Kroměříž, ZL, 767 01, Czechia

  • Anthos Investigative Site

    Holešov, Zlín, 769 01, Czechia

  • Anthos Investigative Site

    Orosháza, BE, 5900, Hungary

  • Anthos Investigative Site

    Baja, BK, 6500, Hungary

  • Anthos Investigative Site

    Budapest, BP, 1036, Hungary

  • Anthos Investigative Site

    Budapest, BP, 1122, Hungary

  • Anthos Investigative Site

    Budapest, BU, 1033, Hungary

  • Anthos Investigative Site

    Budapest, BU, 1134, Hungary

  • Anthos Investigative Site

    Székesfehérvár, FE, 8000, Hungary

  • Anthos Investigative Site

    Debrecen, HB, 4025, Hungary

  • Anthos Investigative Site

    Kaposvár, SO, 7400, Hungary

  • Anthos Investigative Site

    Balatonfüred, VE, 8230, Hungary

  • Anthos Investigative Site

    Balatonfüred, VM, 8230, Hungary

  • Anthos Investigative Site

    Gdynia, GDY, 81-423, Poland

  • Anthos Investigative Site

    Chrzanów, Lesser Poland Voivodeship, 32-500, Poland

  • Anthos Investigative Site

    Krakow, Lesser Poland Voivodeship, 31-202, Poland

  • Anthos Investigative Site

    Wroclaw, Lower Silesian Voivodeship, 51-162, Poland

  • Anthos Investigative Site

    Żarów, Lower Silesian Voivodeship, 58-130, Poland

  • Anthos Investigative Site

    Lublin, Lublin Voivodeship, 20-001, Poland

  • Anthos Investigative Site

    Zamość, Lubusz Voivodeship, 22-400, Poland

  • Anthos Investigative Site

    Płock, Masovian Voivodeship, 09-402, Poland

  • Anthos Investigative Site

    Warsaw, Masovian Voivodeship, 02-097, Poland

  • Anthos Investigative Site

    Warsaw, Masovian Voivodeship, 04-628, Poland

  • Anthos Investigative Site

    Przemyśl, Podkarpackie Voivodeship, 37-700, Poland

  • Anthos Investigative Site

    Gdynia, Pomeranian Voivodeship, 81-157, Poland

  • Anthos Investigative Site

    Bielsko-Biala, Silesian Voivodeship, 43-316, Poland

  • Anthos Investigative Site

    Dąbrowa Górnicza, Silesian Voivodeship, 41-300, Poland

  • Anthos Investigative Site

    Ruda Śląska, Silesian Voivodeship, 41-710, Poland

  • Anthos Investigative Site

    Tychy, Silesian Voivodeship, 43-100, Poland

  • Anthos Investigative Site

    Elblag, Warmian-Masurian Voivodeship, 82-300, Poland

  • Anthos Investigative Site

    Lodz, Łódź Voivodeship, 92-213, Poland

  • Anthos Investigative Site

    Seogu, Busan, 49201, South Korea

  • Anthos Investigative Site

    Seongnam-si, Gyeonggi-do, 13496, South Korea

  • Anthos Investigative Site

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Anthos Investigative Site

    Seoul, Seoul, 158-710, South Korea

  • Anthos Investigative Site

    Seoul, Seoul, 3080, South Korea

  • Anthos Investigative Site

    Seoul, Seoul, 3722, South Korea

  • Anthos Investigative Site

    Taipei, HSZ, 30071, Taiwan

  • Anthos Investigative Site

    Hualien City, HUA, 970, Taiwan

  • Anthos Investigative Site

    Yilan, ILA, 26058, Taiwan

  • Anthos Investigative Site

    Kaohsiung City, KHH, 807, Taiwan

  • Anthos Investigative Site

    Taipei, TPE, 11217, Taiwan

  • Anthos Investigative Site

    Taipei, TPE, 116, Taiwan

  • Anthos Investigative Site

    Tiachung, TXG, 404, Taiwan

  • Anthos Investigative Site (4002)

    Nyíregyháza, SZ, 4400, Hungary

  • Anthos Investigative Site (4003)

    Nyíregyháza, SZ, 4400, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.